A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andrei Iagaru; Stanford University
• Collaborators: General Electric; General Electric Healthcare
• Treatments: Bombesin; Edetic Acid; Gallium 68 PSMA-11; Radiopharmaceuticals

Criteria

Inclusion Criteria:

• Suspected prostate cancer

• Planned prostate biopsy

• Able to provide written consent

• Karnofsky performance status of 50 (or ECOG/WHO equivalent)

Exclusion Criteria:

• Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam

• Metallic implants (contraindicated for MRI)